TABLE 3.
MIC values for different AcrB and AcrA mutants against different substratesa
| Strain | MIC (μg/ml) |
% bile salts | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LMMDs |
HMMDs |
PACs |
|||||||||
| CIP | NAL | ENR | NOR | MIN | TET | ERY | NOV | EB | R6G | ||
| AcrB WT-AcrA WT | 0.015 | 8 | 0.03 | 0.06 | 2 | 2 | 256 | 128 | 512 | >1,024 | 2.5 |
| AcrB WT-AcrA V367G | 0.03 | 4 | 0.06 | 0.12 | 2 | 4 | 256 | 64 | 256 | 256 | 0.625 |
| AcrB WT-AcrA V367S | 0.03 | 8 | 0.06 | 0.12 | 2 | 4 | 128 | 64 | 256 | 256 | 0.625 |
| AcrB WT-AcrA R368A | 0.03 | 4 | 0.015 | 0.12 | 4 | 2 | 256 | 128 | 512 | >1,024 | 2.5 |
| AcrB WT-AcrA R368E | 0.015 | 8 | 0.03 | 0.06 | 2 | 2 | 256 | 128 | 512 | >1,024 | 1.25 |
| AcrB WT-AcrA R368Q | 0.015 | 4 | 0.03 | 0.06 | 2 | 2 | 256 | 128 | 512 | >1,024 | 1.25 |
| AcrB P319L-AcrA WT | 0.03 | 16 | 0.12 | 0.25 | 4 | 4 | 512 | 128 | 512 | >1,024 | 2.5 |
| AcrB P319L-AcrA V367G | 0.06 | 16 | 0.12 | 0.5 | 8 | 4 | 512 | 256 | 512 | >1,024 | 2.5 |
| AcrB P319L-AcrA V367S | 0.06 | 16 | 0.25 | 0.5 | 8 | 8 | 512 | 512 | 512 | >1,024 | 5 |
| AcrB P319L-AcrA R368A | 0.06 | 16 | 0.12 | 0.25 | 4 | 2 | 512 | 256 | 512 | >1,024 | 2.5 |
| AcrB P319L-AcrA R368E | 0.03 | 8 | 0.06 | 0.12 | 2 | 2 | 256 | 128 | 256 | >1,024 | 1.25 |
| AcrB P319L-AcrA R368Q | 0.03 | 8 | 0.06 | 0.06 | 2 | 2 | 256 | 128 | 256 | 1,024 | 1.25 |
MIC values for the substrates nalidixic acid (NAL), ciprofloxacin (CIP), enrofloxacin (ENR), norfloxacin (NOR), erythromycin (ERY), novobiocin (NOV), minocycline (MIN), tetracycline (TET), ethidium bromide (EtBr), and rhodamine 6G (R6G) are shown. LMMDs, low-molecular-mass drugs; HMMDs, high-molecular-mass drugs; PACs, planar aromatic cations. The bold text indicates that the MIC value is different from that of the AcrB WT-AcrA WT strain.